Lung cancer genetic drivers study at CRO Aviano
Part of Cancer, Lungs & breathing clinical trials.
This study is looking at people with non-small cell lung cancer (NSCLC) to find certain genetic changes that drive the cancer. It may help doctors understand which treatments could work best for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your first visit or admission to the Cancer Institute in Aviano (CRO) must be between September 2023 and September 2028.
- You must have a diagnosis of non-small cell lung cancer (NSCLC) at any stage.
- Your tumor must be confirmed to come from the lung (not a cancer that started elsewhere and spread to the lung).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples from people with non-small cell lung cancer (NSCLC) either before or after treatment. It aims to help researchers learn more about how tumors respond, especially in cancers with specific genetic changes or after certain pre-surgery therapies.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This trial looks at the “molecular landscape,” meaning the specific gene changes driving your lung cancer, for people whose non-small cell lung cancer (NSCLC) has rare mutations. The goal is to better understand what those rare changes mean and how they could guide treatment decisions.
This trial is part of a lung cancer network that uses genetic (DNA) testing to better understand and treat non-surgical lung cancer. You might be eligible if you have certain stages of non-small cell lung cancer and can consent to participate.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.